Abstract：
Acanthosis nigricans (AN) is characterized by dark, velvety patches and thin plaques primarily in the body folds. AN is more prevalent in skin of color populations, including Black/African American, Native American, and Hispanic patients. As the U.S. population becomes increasingly diverse, the need for inclusive dermatologic research becomes more pressing. Given the increased prevalence of AN in skin of color patients, there is a need to evaluate representation in AN clinical trials. This study aims to uncover gender, race, ethnicity, and Fitzpatrick skin type (FST) representation in AN clinical trials. A systematic literature search was performed across PubMed, Embase, and Cochrane databases to identify participant characteristics in clinical trials focused on AN treatment. Our review yielded 21 clinical trials, totaling 575 participants, with an identified predominance of female participants (69.0%) and a surprising absence of race or ethnicity data. Out of the 11 studies that included FST data, 1.2% of participants were type II, 20.6% were type III, 50.0% were type IV, and 28.2% were type V. None of the participants were FST I or VI. Herein, we highlight a predominate inclusion of female and FST III-V patients in AN clinical trials, the populations most impacted by this condition. We also highlight the need for improved race and ethnicity reporting and the importance of including all FSTs in clinical studies. Addressing this gap is critical for developing safe, efficacious, patient-centered, and equitable treatments for all AN patients. Future research should prioritize comprehensive inclusion of race, ethnicity, and the full spectrum of FSTs.
摘要：
黑棘皮病（AN）的特点是黑暗，天鹅绒般的斑块和薄斑块主要在身体褶皱。AN在有色人种的皮肤中更为普遍，包括黑人/非裔美国人，美洲原住民,和西班牙裔患者。随着美国人口越来越多样化，包容性皮肤病学研究的需求变得更加紧迫。鉴于有色人种患者皮肤中AN的患病率增加，有必要评估临床试验中的代表性。这项研究旨在揭示性别，种族,种族,和Fitzpatrick皮肤类型（FST）在临床试验中的代表。在PubMed进行了系统的文献检索，Embase,和Cochrane数据库，以确定专注于AN治疗的临床试验中的参与者特征。我们的综述产生了21项临床试验，共有575名参与者，确定女性参与者占主导地位（69.0％），并且没有种族或族裔数据。在包括FST数据的11项研究中，1.2%的参与者是II型，20.6%为III型，50.0%为IV型，28.2%为V型。在这里，我们强调在AN临床试验中主要包括女性和FSTIII-V患者，受这种情况影响最大的人群。我们还强调了改善种族和种族报告的必要性，以及将所有FST纳入临床研究的重要性。解决这一差距对于发展安全，有效的，以病人为中心,对所有患者进行公平的治疗。未来的研究应该优先考虑全面纳入种族，种族,和全谱的FST。
